Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Comment by TriumphSpitSixon Dec 05, 2020 1:52pm
203 Views
Post# 32044227

RE:RE:RE:RE:RE:Looks good to me

RE:RE:RE:RE:RE:Looks good to me Ok, so it looks like I may have had causality backwards. It's Jed Woods who is the shark and had a pre-existing financial relationship with HEM. Looks like he brought Makofka in as his "tool" to restructure the company out of public existence and into his private control.

milstogo wrote: Exactly.

I'm thinking Jeb Wood might be the one Kyle Makofka's talking about in that interview from September 2019
. https://bioinformant.com/hemostemix/

When he starts out saying: 


"I first became involved with Hemostemix when a longtime friend and business partner came to me with some concerns around an investment his Family Office had made in the company. He has a long track record of success and felt this organization had a disruptive technology but was underperforming in its execution. I was also intrigued by Hemostemix and its potential, as it did have what appeared to be an industry changing technology, however the company had not streamlined internal processes, lacked strategic vision and needed cash to support its growth trajectory."


(his family office probably includes his kids)
 



<< Previous
Bullboard Posts
Next >>